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Background: The aim of our study was to evaluate the functional and anatomic outcomes 
of intravitreal ranibizumab for the treatment of symptomatic drusenoid pigment epithelial 
detachment without choroidal neovascularization in age-related macular degeneration.
Methods: This was a prospective, single-center, uncontrolled, interventional pilot study. 
Six consecutive eyes (six patients) with drusenoid pigment epithelial detachment with a visual 
acuity of 20/63 to 20/100 and no evidence of choroidal neovascularization in age-related 
macular degeneration participated. Patients were given at least one intravitreal ranibizumab 
injection and were followed for a mean of 66.67 ± 10.3 weeks. Main outcome measures included 
best-corrected visual acuity (BCVA) measured by Early Treatment Diabetic Retinopathy Study 
charts and optical coherence tomography, and central macular thickness measured by optical 
coherence tomography.
Results: The mean number of intravitreal ranibizumab injections was 3.0 at the end of follow-up. 
Regarding BCVA and optical coherence tomography, 33.3% of eyes gained between 19 and 
21 letters of BCVA, with a median decrease in central macular thickness of 21 µm. There was 
a statistically significant difference between baseline and final BCVA (P = 0.046). There was 
a positive correlation between intraretinal fluid by optical coherence tomography and improved 
BCVA after intravitreal ranibizumab. Metamorphopsia disappeared completely after the first 
injection in all subjects, with no further recurrences. No patient developed choroidal neovascu-
larization or atrophic changes.
Conclusion: Intravitreal ranibizumab demonstrated anatomic and functional benefit in patients 
with symptomatic drusenoid pigment epithelial detachment without choroidal neovascularization 
in age-related macular degeneration. Further long-term, randomized, controlled trials should 
be performed to confirm our preliminary results.
Keywords: age-related macular degeneration, choroidal neovascularization, drusenoid pigment 
epithelial detachment, ranibizumab, soft drusen
Introduction
Detachment of the retinal pigment epithelium is a common manifestation of age-related 
macular degeneration. It can be classified as fibrovascular, serous, hemorrhagic, and 
drusenoid.1,2 Drusenoid pigment epithelial detachment appears as a result of the slow 
coalescence of soft drusen, and it has been distinguished from the other types of pigment 
epithelial detachment by its relatively better prognosis.3–6 However, the natural history 
usually follows a progression to persistent drusenoid pigment epithelial detachment, 
geographic atrophy, and neovascularization.7,8Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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No treatment has been standardized for drusenoid pigment 
epithelial detachment. Oral antioxidant   supplementation 
intake is the only treatment suggested to reduce the   incidence 
of geographic atrophic and neovascular complications 
in patients with soft drusen and dry age-related macular 
degeneration.8 Macular laser photocoagulation to reduce 
drusen has been used with variable, controversial, and contra-
dictory results.10–13 The use of verteporfin photodynamic 
therapy14 or intravitreal pegaptanib15 has been reported 
in drusenoid pigment epithelial detachment, resulting in 
secondary atrophy with poor visual outcomes. In the same 
way, a recent report informed about the favorable outcomes 
of the use of intravitreal bevacizumab, with visual recovery 
in three cases.16 The objective of this pilot study was to 
evaluate the functional and anatomic outcomes of intravitreal 
ranibizumab for the treatment of symptomatic drusenoid 
pigment epithelial detachment without choroidal neovascu-
larization in age-related macular degeneration.
Patients and methods
This prospective, single-center, uncontrolled, interven-
tional pilot study was conducted at the University Hospital 
La Fe, Valencia, Spain. Approval was obtained from the 
Institutional Ethics Committee, and informed consent was 
obtained for this study. In addition, the study was performed 
in accordance with the ethical standards laid down in the 
1964 Declaration of Helsinki. The off-label use of the drug 
for this indication, and its potential risks and benefits, were 
discussed extensively with all patients.
Eligible subjects were at least 50 years of age.   Eligibility 
criteria for a study eye included the following: Early Treatment 
Diabetic Retinopathy Study (ETDRS)   best-corrected visual 
acuity (BCVA) lower than 20/30; drusenoid pigment 
epithelial detachment from age-related macular degeneration 
defined clinically as a focal area of at least 1/2 disc diameter 
of confluent soft drusen under the center of the macula 
with faint hypofluoresecence in the early frames of the 
fluorescein angiogram which increased progressively but 
stabilized in the late phases, without leakage, and defined 
tomographically as a focal elevation of the retinal pigment 
epithelium contour associated with fluid beneath the 
elevation but without coexistent shadowing; and presence 
of metamorphosia. Exclusion criteria included angiographic 
evidence of choroidal neovascularization; prior treatment 
with   photodynamic therapy, intravitreal corticosteroids, 
or vascular endothelial growth factor inhibitors (at any 
time); peribulbar steroid injection (within the previous six 
months) or pars plana vitrectomy (at any time); history of 
uncontrolled glaucoma; retinal vascular disorder potentially 
related to macular edema; and intraocular pressure of 
25 mmHg or more.
At baseline and at each follow-up visit, ETDRS BCVA 
letter score was measured. After pupil dilatation, optical 
coherence tomography images were obtained at baseline and 
at each follow-up visit using spectral-domain optical coherence 
tomography (Cirrus High-Definition OCT, Carl Zeiss Meditec, 
Dublin, CA). The scans employed included a Macular Cube 
512 × 128, performing two scans and using the average of 
the two central subthreshold thicknesses for the analysis, 
and five radial lines to obtain high-resolution images of the 
study eye. Additional testing included slit-lamp examination, 
dilated fundus examination, posterior pole retinography, and 
measurement of intraocular pressure with a pneumotonometer. 
Subjects were asked to report the main symptoms they were 
complaining of. The presence of metamorphopsia was assessed 
by the red-lined black Amsler grid as described in previous 
reports.17 Fluorescein angiography was performed at baseline, 
and it was repeated only when there was a decrease in BCVA 
and/or fundus examination or optical coherence tomography 
findings suggested choroidal neovascularization.
At baseline, every patient underwent a single intravitreal 
injection of 0.5 mg/0.05 mL of ranibizumab (Lucentis®, 
Genentech, South San Francisco, CA). The intravitreal 
injection of ranibizumab followed a standardized protocol. 
Using topical anesthesia followed by a povidone-iodine 
preparation, ranibizumab was injected into the vitreous 
cavity 4.0 mm posterior to the limbus in the inferotemporal 
quadrant. After the injection, povidone-iodine was dropped 
again into the conjunctival fornix and topical gentamicin 
ointment was applied.
Patients were scheduled for monthly follow-up. Retreatment 
criteria included persistence or recurrence of focal elevation of 
the retinal pigment epithelium contour on optical coherence 
tomography, persistence or recurrence of intraretinal fluid on 
optical coherence tomography, or loss of more than five ETDRS 
letters when compared with the prior examination.
Results
The study period was from December 2007 to December 
2008, and six consecutive subjects (mean age ± standard 
deviation [SD], 69 ± 2.9; 66.7% women) were enrolled, all of 
them with one eye affected with drusenoid pigment epithelial 
detachment. At baseline, the mean BCVA in the study eyes 
was 0.40 ± 0.15 [decimal ETDRS equivalent] and the mean 
central macular thickness was 287.83 ± 23.25 µm. Additional 
demographic characteristics of the six subjects are reported 
in Table 1. The mean follow-up duration for the study was 
66.67 ± 10.3 (median 68.5, range 52–80) weeks.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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All eyes received intravitreal ranibizumab at baseline. 
After this first injection, the mean number of retreatments 
was 2.0 at the end of follow-up. One (16.6%) patient showed 
stabilization of the retinal pigment epithelium contour by 
optical coherence tomography and absence of symptoms after 
one intravitreal ranibizumab injection through 67 weeks of 
follow-up and required no retreatment. One (16.6%) patient 
required one retreatment at week 24 because of recurrence 
with a total of 52 weeks of follow-up. Two (33.3%) patients 
required two retreatments with 58 (at weeks 12 and 36) and 
73 (at weeks 16 and 44) weeks of follow-up. The other two 
(33.3%) patients were retreated three (at weeks 16, 36, and 
64) and four times (at weeks 8, 28, 36, and 56) with a total 
of 80 and 71 weeks’ follow-up, respectively (Table 2).
Regarding BCVA, 33.3% of patients gained between 19 
to 21 letters of BCVA at the end of follow-up. The mean 
final BCVA was 0.58 ± 0.3 (decimal ETDRS equivalent). No 
patient experienced loss of BCVA during the study period. 
There was a statistically significant difference between 
baseline and final BCVA after intravitreal ranibizumab 
(P = 0.046, Table 2).
The mean final central macular thickness in the study 
eyes was 273.50 ± 12.74 µm. The median decrease in central 
macular thickness from baseline at the end of follow-up was 
21 µm (P = 0.18). Only one (16.6%) eye showed a minimal 
increase in central macular thickness of 2 µm; the other 
five (83.3%) patients showed a mean decrease in central 
macular   thickness of 17.6 ± 13.2 µm. All these changes 
were not statistically significant. However, there was a 
  positive correlation between intraretinal fluid by optical 
coherence tomography and improved BCVA after   intravitreal 
ranibizumab. The patient with the better visual outcome 
(subject 3), had a BCVA improvement from 20/50 to 20/20, 
with a higher decrease in central macular thickness from 315 
to 279 µm (Figures 1 and 2).
We evaluated changes in visual symptoms in terms of 
persistence or recurrence of metamorphopsia. All patients 
examined with the red-lined black Amsler grid showed 
disappearance of metamorphopsia after the first intravitreal 
ranibizumab injection. The disappearance of metamorphopsia 
was independent of whether there was an improvement or 
not in BCVA. There was no recurrence of metamorphopsia 
during the follow-up period.
Discussion
In this prospective, single-center, uncontrolled, interventional 
pilot study, six eyes (from six patients) with drusenoid 
pigment epithelial detachment with a visual acuity of 20/63 
to 20/100 and no evidence of choroidal neovascularization 
in age-related macular degeneration were given a mean of 
three intravitreal ranibizumab injections and were followed 
for a mean of 66.67 ± 10.3 weeks. One third of the eyes 
Table 1 Baseline subject characteristics
Subject Age Gender Baseline BCVA CMT Lens Visual symptoms
Snellen Letters Decimal
1 73 Female 20/63 26 0.32 286 Pseudoaphakic Blurred vision  
and metamorphopsia
2 71 Female 20/63 28 0.32 269 Phakic Metamorphopsia
3 67 Male 20/50 33 0.4 315 Phakic Blurred vision  
and metamorphopsia
4 65 Female 20/32 42 0.63 273 Phakic Metamorphopsia
5 70 Male 20/40 37 0.5 266 Pseudoaphakic Blurred vision  
and metamorphopsia
6 68 Female 20/100 19 0.2 318 Phakic Blurred vision  
and metamorphopsia
Abbreviations: BCVA, best-corrected visual acuity; CMT, central subfield thickness.
Table 2 Final visit characteristics of patients undergoing intravitreal ranibizumab treatment
Subject Final BCVA CMT Visual symptoms Follow-up time 
(weeks)
Treatments (n)
Snellen Letters Decimal
1 20/63 29 0.32 278 none 58 3
2 20/25 47 0.80 263 none 52 2
3 20/20 55 1.00 279 none 66 1
4 20/32 44 0.63 275 none 73 3
5 20/40 38 0.50 255 none 80 4
6 20/100 19 0.20 291 none 71 5
Abbreviations: BCVA, best-corrected visual acuity; CMT, central subfield thickness.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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gained between 19 and 21 letters of BCVA, with a median 
decrease in central macular thickness of 21 µm. There was a 
statistically significant difference between baseline and final 
BCVA. Metamorphopsia disappeared completely after the first 
injection in all subjects, with no further recurrences. No patient 
developed choroidal neovascularization or atrophic changes.
Drusenoid pigment epithelial detachment has a   particular 
evolution and potential risks for severe loss of visual acuity, 
and it should be considered as a subgroup of age-related 
macular degeneration. The natural history has been defined as 
progression to persistent drusenoid pigment epithelial detach-
ment, geographic atrophy, or choroidal neovascularization.18,19 
However, no treatment has been established for drusenoid 
pigment epithelial detachment. Antivascular endothelial 
growth factor therapies15,16 have shown variable anatomical 
and visual outcomes.
Intravitreal ranibizumab seems to be beneficial in patients 
with drusenoid pigment epithelial detachment, especially when 
intraretinal fluid is present by optical coherence tomography. 
The exact mechanism by which antivascular endothelial growth 
factor therapies show promising outcomes is still unknown. 
In addition, none of our patients developed choroidal neovascu-
larization or geographic atrophy. In a retrospective review, the 
risk of developing choroidal neovascularization in drusenoid 
pigment epithelial detachment was determined to be 11% at 
three years, 23% at five years, and 25% after 10 years.7 A recent 
report from the Age-Related Eye Disease Study group8 showed 
that 376 (7.9%) of the 4757 patients included in the study 
presented with clinical features of drusenoid pigment epithe-
lial detachment; after five years of follow-up, the incidence 
of choroidal neovascularization increased from 9% to 25% 
of these eyes, whereas the incidence of geographic atrophy 
increased from 0.3% to 5% of them. In conclusion, the total 
proportion of eyes with advanced age-related macular degen-
eration increased from 9% to 48%, suggesting that drusenoid 
pigment epithelial detachment is an independent risk factor 
for advanced age-related macular degeneration. Despite the 
short-term follow-up (mean 66.67 weeks) and the limited 
number of eyes included in our study, according to these data, 
we should have found some degree of loss of visual acuity as a 
consequence of atrophic or neovascular changes, although the 
lack of a control group in the present study makes it impossible 
to offer conclusive data.
In summary, intravitreal ranibizumab demonstrated 
anatomic and functional benefit in patients with symptomatic 
drusenoid pigment epithelial detachment without choroidal 
neovascularization in age-related macular degeneration. 
Further long-term, randomized, controlled trials should be 
performed to confirm our preliminary results in order to 
provide us with some guidelines to treat these drusenoid 
pigment epithelial detachments before they progress to 
atrophic or neovascular changes within the foveal area 
where they are located and, therefore, prevent the visual loss 
associated with this phenomenon.
Figure 1 subject 3: Baseline visit. A 67-year-old male complained of blurred vision 
on his left eye. Retinography demonstrates soft confluent drusen within the macular 
area (top left). Best-corrected visual acuity was 20/50. Optical coherence tomography 
revealed a drusenoid pigment epithelial detachment, and microcystic hyporreflective 
spaces within the neurosensory retina and an elevated retinal map (bottom left). 
Fluorescein angiography did not show any choroidal neovascularization associated 
(top and bottom right).
Figure 2 subject 3: Final visit. retinal pigment epithelium returned to a normal 
contour and no fluid was evident within the retina 66 weeks after a single injection 
of intravitreal ranibizumab (top and bottom). Best-corrected visual acuity improved 
to 20/20 and remained stable through the follow-up period. no visual complaint 
was referred.Clinical Ophthalmology
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